荧光原位杂交市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

荧光原位杂交市场按产品类型(分析仪器、试剂盒和试剂、软件和服务)、应用和地理位置进行细分。

荧光原位杂交市场快照

Fluorescent In Situ Hybridization Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

由于癌症和遗传疾病等疾病的高发率,预计荧光原位杂交市场将得到推动。根据世界卫生组织的数据,目前约有 10,000 和更多的疾病是单基因的。单基因疾病是指单个基因的修饰。此外,根据世界卫生组织的数据,癌症是导致死亡的主要原因之一,2017 年全球有 960 万人死于癌症。此外,产品的新兴趋势预计将推动市场增长。例如,2018 年,Sysmex Corporation 推出了用于研究目的的荧光原位杂交测试软件系统。因此,这些因素有望增加对荧光原位杂交的需求。

报告范围

荧光原位杂交 (FISH) 主要用于诊断目的,涉及与非常互补的核酸结合的荧光探针。荧光原位杂交市场按产品类型、应用和地理位置进行细分。

By Product Type
Analytical Instrument
Kits & Reagents
Software & Services
By Application
Cancer
Genetic Diseases
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

癌症细分市场预计将在荧光原位杂交市场显着增长

• 体外诊断的日益普及和癌症负担的增加预计将成为推动这一特定领域市场的主要因素。细胞遗传学技术在癌症染色体异常的检测中起着至关重要的作用。根据世界卫生组织的数据,肺癌是主要诊断癌症之一,2018 年全球有 209 万例病例。

• 此外,根据Publicliterature of Science 的研究,荧光原位杂交技术在检测非小细胞肺癌的MET(肝细胞生长受体因子)基因异常方面非常有效。因此,预计这些因素将对荧光原位杂交市场的癌症部分产生积极影响。

Fluorescent In Situ Hybridization Market

北美预计将在市场上占有重要份额,预计在预测期内也将如此

由于慢性病的患病率较高以及与 FISH 相关的产品批准不断增加,预计北美将成为荧光原位杂交市场的主导地区。例如,2019 年,Oxford Gene Technology 获得了美国 FDA(食品和药物管理局)对八种鱼类探针的批准,这些探针将参与检测急性髓性白血病(AML)和骨髓增生异常综合征(MDS)。根据美国癌症协会的数据,2020 年的癌症发病率估计为 180 万。因此,有望推动荧光原位杂交市场的增长。

Fluorescent In Situ Hybridization Market - Growth Rate by Region

竞争格局

公司采取的战略举措有望推动荧光原位杂交市场。例如,2016 年,安捷伦科技与应用光谱成像 (ASI) 合作开发和销售安捷伦的 FISH 产品和 ASI 的成像软件。目前主导市场的一些公司包括 Abnova Corporation、Genemed Technologies, Inc.、Biocare Medical, LLC、Qiagen (Exiqon A/S)、Agilent Technologies、Merck KGaA、Biodot Inc.、PERKINELMER Inc.、ThermoFisher Scientific Inc. ., 和 F. HOFFMANN-LA ROCHE LTD.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Chronic Disease

      2. 4.2.2 Product Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness about Emerging Diagnostic Technologies in Cytogenetics

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Analytical Instrument

      2. 5.1.2 Kits & Reagents

      3. 5.1.3 Software & Services

    2. 5.2 By Application

      1. 5.2.1 Cancer

      2. 5.2.2 Genetic Diseases

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abnova Corporation

      2. 6.1.2 Agilent Technologies

      3. 6.1.3 Biocare Medical, LLC

      4. 6.1.4 Biodot Inc.

      5. 6.1.5 F. HOFFMANN-LA ROCHE LTD.

      6. 6.1.6 Genemed Technologies, Inc.

      7. 6.1.7 Merck KGaA

      8. 6.1.8 PERKINELMER INC

      9. 6.1.9 Qiagen (Exiqon A/S)

      10. 6.1.10 ThermoFisher Scientific Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Fluorescent In Situ Hybridization Market market is studied from 2018 - 2026.

The Fluorescent In Situ Hybridization Market is growing at a CAGR of 6.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

ThermoFisher Scientific Inc. , Agilent Technologies , Genemed Technologies Inc. , PERKINELMER Inc., F. HOFFMANN-LA ROCHE LTD. are the major companies operating in Fluorescent In Situ Hybridization Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!